Rare diseases
Investigational molecules
Locations
Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer
NorwayStudy of Drug Combination for Advanced Cancer Patients with Known Molecular Profile - FINPROVE Study
FinlandStudy on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma
The NetherlandsStudy of drug combination in patients with advanced cancer based on genomic profiling - ProTarget Danish nationwide trial
DenmarkStudy of Pemigatinib and Retifanlimab for Patients with Advanced Dedifferentiated Liposarcoma
DenmarkStudy of Pemigatinib for Patients with Recurrent or Metastatic Solid Tumors with FGFR Gene Alteration
FranceMolecularly Tailored Therapy Versus Standard Care in Patients With Advanced Pancreatic Cancer Using Olaparib, Erlotinib, Crizotinib, Trametinib, Pemigatinib, Selpercatinib, Axitinib, Vismodegib, Pembrolizumab, Larotrectinib, Dabrafenib, Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan, Gemcitabine, Paclitaxel Albumin-Bound, and Calcium Folinate
DenmarkStudy of Pemigatinib for Patients with Advanced Intrahepatic Cholangiocarcinoma with FGFR2 Changes After Local Therapy
GermanyStudy Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement
AustriaStudy of Retifanlimab Alone and in Combination with Drug Therapy for Adults with Advanced or Metastatic Endometrial Cancer Who Have Not Responded to Platinum Chemotherapy
BelgiumContinued Treatment Study for Adults with Advanced Cancer Using Pemigatinib
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.
